Advanced Biomed Launches 120-Patient Study to Validate 3D Cell Culture Platform for Precision Cancer Treatment
核心洞察
Advanced Biomed Inc. (搜索) has initiated a 120-case feasibility study with Chi-Mei Medical Center (搜索) to evaluate the predictive accuracy of its A+PerfusC (搜索)™ 3D cell culture platform for oncology treatment selection.
The study will compare ex-vivo drug sensitivity results from circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes to assess correlation and predictive performance.
The A+PerfusC (搜索) platform uses label-free microfluidic technology to isolate circulating tumor cells and grows them in automated 3D culture arrays for parallel drug testing.
Advanced Biomed Inc. (搜索) (Nasdaq: ADVB) has launched a clinical research collaboration with Chi-Mei Medical Center (搜索) to evaluate its A+PerfusC (搜索)™ 3D cell culture platform in a 120-case feasibility study. The non-interventional study, which received Institutional Review Board approval, began case collection in early February 2026 and aims to validate the platform's ability to predict cancer treatment responses through functional drug sensitivity testing.
Study Design and Timeline
The feasibility study will compare ex-vivo drug sensitivity results generated by the A+PerfusC (搜索) platform from circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes to assess correlation and predictive performance. Interim comparative data is expected in May-June 2026, with full study completion targeted by year-end 2026.
The study follows Advanced Biomed's September 2025 commercial launch of the A+PerfusC (搜索) integrated perfusion 3D cell culture platform and represents a critical step toward demonstrating real-world clinical utility for the technology.
Addressing Current Treatment Selection Limitations
The collaboration seeks to address fundamental limitations in current oncology treatment selection approaches. Two-dimensional cell culture models and xenograft animal models frequently fail to recapitulate the complex, patient-specific biology of human tumors and are constrained by low throughput and long turnaround times.
The A+PerfusC (搜索) platform offers a different approach by isolating high-viability circulating tumor cells using label-free microfluidic technology and growing them in automated 3D culture arrays that enable parallel testing of multiple drugs and combinations. This functional, patient-derived testing approach aims to shorten the time to evidence-based treatment decisions, reduce exposure to ineffective therapies and their toxicities, and provide clinicians with a practical tool to prioritize therapies most likely to benefit individual patients.
Technology Platform Advantages
Beyond direct patient impact, the platform addresses practical and ethical constraints associated with animal-based models. Replacing large cohorts of mice with high-density arrays of patient-derived tumor spheroids enables high-throughput screening that is not feasible with xenografts. Advanced Biomed's automated A+PerfusC (搜索)™ system is designed to reduce labor intensity and scale functional testing to clinically actionable timeframes.
"We believe the A+PerfusC (搜索) platform can materially improve how oncologists select therapies by delivering patient-specific, functional drug sensitivity data derived from a minimally invasive liquid biopsy," said Dr. Yi Lu, Chief Executive Officer of Advanced Biomed. "This feasibility study with Chi-Mei Medical Center (搜索) is a critical step toward demonstrating the platform's real-world predictive value and advancing precision oncology beyond genomic inference to functional, individualized testing."
Future Development Plans
Advanced Biomed expects the feasibility study's results to inform the design of subsequent, larger clinical validation studies and to support the platform's use as a predictive tool for treatment response and Clinical Decision Support (CDS), pending favorable outcomes and regulatory review.
Under the collaboration agreement, Advanced Biomed and Chi-Mei Medical Center (搜索) will jointly conduct the non-commercial clinical research and collaborate on subsequent commercial development. Both parties will share rights to project-related intellectual property and research outcomes.
Advanced Biomed operates through a subsidiary in Taiwan and has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell detection, enrichment, and analysis. The company's portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.